A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Abhijeet Kumar
Sponsor
AbbVie Incorporated
Unit
Cancer Center Division